Cognition Therapeutics Stock Price Patterns
| CGTX Stock | USD 1.12 0.05 4.67% |
Momentum 34
Sell Stretched
Oversold | Overbought |
EPS Estimate Next Quarter (0.08) | EPS Estimate Current Year (0.39) | EPS Estimate Next Year (0.34) | Wall Street Target Price 3.5 | EPS Estimate Current Quarter (0.09) |
Using Cognition Therapeutics hype-based prediction, you can estimate the value of Cognition Therapeutics from the perspective of Cognition Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Cognition Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Cognition because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Cognition Therapeutics after-hype prediction price | USD 1.17 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Cognition | Build AI portfolio with Cognition Stock |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cognition Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cognition Therapeutics After-Hype Price Density Analysis
As far as predicting the price of Cognition Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Cognition Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Cognition Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Cognition Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Cognition Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Cognition Therapeutics' historical news coverage. Cognition Therapeutics' after-hype downside and upside margins for the prediction period are 0.06 and 6.33, respectively. We have considered Cognition Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Cognition Therapeutics is dangerous at this time. Analysis and calculation of next after-hype price of Cognition Therapeutics is based on 3 months time horizon.
Cognition Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Cognition Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cognition Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Cognition Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.16 | 5.16 | 0.05 | 0.06 | 12 Events / Month | 6 Events / Month | In about 12 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
1.12 | 1.17 | 4.46 |
|
Cognition Therapeutics Hype Timeline
Cognition Therapeutics is currently traded for 1.12. The entity has historical hype elasticity of 0.05, and average elasticity to hype of competition of 0.06. Cognition is anticipated to increase in value after the next headline, with the price projected to jump to 1.17 or above. The average volatility of media hype impact on the company the price is over 100%. The price jump on the next news is projected to be 4.46%, whereas the daily expected return is currently at -0.16%. The volatility of related hype on Cognition Therapeutics is about 1425.41%, with the expected price after the next announcement by competition of 1.18. Cognition Therapeutics currently holds about 46.61 M in cash with (28.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. Given the investment horizon of 90 days the next anticipated press release will be in about 12 days. Check out Cognition Therapeutics Basic Forecasting Models to cross-verify your projections.Cognition Therapeutics Related Hype Analysis
Having access to credible news sources related to Cognition Therapeutics' direct competition is more important than ever and may enhance your ability to predict Cognition Therapeutics' future price movements. Getting to know how Cognition Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Cognition Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| TVGN | Tevogen Bio Holdings | 0.02 | 6 per month | 0.00 | (0.12) | 10.00 | (8.33) | 26.81 | |
| VTGN | VistaGen Therapeutics | 0.05 | 8 per month | 0.00 | (0.15) | 7.93 | (12.80) | 96.59 | |
| SRZN | Surrozen | (2.02) | 7 per month | 4.47 | 0.19 | 13.34 | (10.10) | 34.29 | |
| SEER | Seer Inc | 0.02 | 6 per month | 1.49 | (0.02) | 3.72 | (2.21) | 7.59 | |
| GLSI | Greenwich Lifesciences | 4.38 | 9 per month | 6.04 | 0.23 | 19.77 | (11.54) | 36.51 | |
| ATOS | Atossa Genetics | 0.52 | 10 per month | 0.00 | (0.24) | 6.75 | (9.93) | 42.59 | |
| SPRO | Spero Therapeutics | (0.05) | 5 per month | 0.00 | (0.03) | 3.81 | (5.04) | 13.07 | |
| IRD | Opus Genetics | 0.14 | 7 per month | 3.85 | 0.21 | 9.77 | (7.41) | 22.40 | |
| AGEN | Agenus Inc | 0.34 | 15 per month | 0.00 | (0.1) | 6.63 | (6.79) | 30.06 | |
| MCRB | Seres Therapeutics | 0.22 | 7 per month | 0.00 | (0.06) | 7.45 | (11.49) | 71.55 |
Cognition Therapeutics Additional Predictive Modules
Most predictive techniques to examine Cognition price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Cognition using various technical indicators. When you analyze Cognition charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Cognition Therapeutics Predictive Indicators
The successful prediction of Cognition Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Cognition Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Cognition Therapeutics based on analysis of Cognition Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Cognition Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Cognition Therapeutics's related companies. | 2025 | 2026 (projected) | Payables Turnover | 0.0658 | 0.0417 | Days Of Inventory On Hand | 474.5 | 421.78 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cognition Stock Analysis
When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.